SOURCES SOUGHT
65 -- BLOOD AND BLOOD PRODUCTS
- Notice Date
- 10/7/2022 2:37:34 PM
- Notice Type
- Sources Sought
- NAICS
- 325414
— Biological Product (except Diagnostic) Manufacturing
- Contracting Office
- 256-NETWORK CONTRACT OFFICE 16 (36C256) RIDGELAND MS 39157 USA
- ZIP Code
- 39157
- Solicitation Number
- 36C25623Q0041
- Response Due
- 10/13/2022 1:00:00 PM
- Archive Date
- 10/23/2022
- Point of Contact
- lakeisha.white@va.gov, Lakeisha White, Phone: 601-206-6959
- E-Mail Address
-
Lakeisha.White@va.gov
(Lakeisha.White@va.gov)
- Awardee
- null
- Description
- Department of Veterans Affairs Network Contracting Office (NCO) 16 Request For Information (RFI) DISCLAIMER: THIS IS A SOURCES SOUGHT NOTICE ONLY. THIS SYNOPSIS IS NOT A REQUEST FOR QUOTE, PROPOSAL, OR BID. This notice is not a solicitation as defined by FAR 2.101, therefore it shall not be construed as a commitment by the Government to enter into a contract, nor does it restrict the Government to an acquisition approach. All information contained in this Request for Information (RFI) is preliminary as well as subject to amendment and is in no way binding on the Government. Information submitted in response to this notice is voluntary; the Government will not pay for information requested nor will it compensate any respondent for any cost incurred in developing information provided to the Government. The Government is requesting that restrictive or proprietary markings not be used in response to this notice. If a solicitation is released, it will be synopsized in the Federal Contract Opportunities website or GSA. It is the responsibility of the interested parties to monitor these sites for additional information pertaining to this RFI 1. Title: __Blood and Blood Products _(Central Arkansas Veterans Healthcare System) ____________ 2. Purpose: The purpose of this RFI is to identify potential sources which will aid in defining the procurement strategy (e.g., set-aside, sole source, unrestricted) for a solicitation the VA intends on issuing shortly for the following: 16B Leukoreduced Red Blood Cells (Prestorage) L03 Antibody Screen 16I Irradiated Leukoreduced Red Blood Cells (Prestorage) L04 Antibody Identification 16CP Leukoreduced Red Blood Cells CPD Unit 04A Cold Agglutinin Low Temperature Screen 16CPI Irradiated Leukoreduced Red Blood Cells CPD Unit 04B Antibody Elution and Red Cell Panel 20 Autologous Red Blood Cells (Prestorage Leukoreduced) 04E Antibody Absorption and Red Cell Panel 24C Autologous Red Blood Cells - Collected by Apheresis 04F Additional Red Cell Antibody Panel 44 Cryoprecipitate - Whole Blood Derived (from 200 ml plasma) L08 After-Hours Tech Call Fee: Surcharge per patient request 44PD5 Pooled Cryoprecipitate - (5) Whole Blood Derived RH2 C Antigen Type 61 Leukoreduced Platelets - Collected by Apheresis (Full Dose> or = 3.0X10(11)) RH3 E Antigen Type 61I Irradiated Leukoreduced Platelets - Collected by Apheresis (Full Dose> or = 3.0X10(11)) RH4 c Antigen Type 62 Leukoreduced Platelets - Collected by Apheresis (HLA Matched) (Full Dose) RH5 e Antigen Type 63 Leukoreduced Platelets - Collected by Apheresis (Partial Dose) RH8 Cw Antigen Type 40 AFFP (250 +/- 25ml) x2 Apheresis Derived MS1 M Antigen Type 40PED AFFP (100 +/- 10ml) x1 Apheresis Derived MS2 N Antigen Type 42PED FP-24 (Frozen < 24 hours) 1 x 100ml (100 +/- 10ml) MS3 S Antigen Type 40-2 AFP-24 ( 250 + 25ml) x 1 Apheresis Derived MS4 s Antigen Type 42 FFP-WBD 1 x 250ml (250 + 25 ml) Whole Blood Derived K1 K Antigen Type 42HR FP-24 (Frozen < 24 hours) 1 x 250ml (250 + 25ml) K2 k Antigen Type 40CCP COVID-19 Convalescent Plasma (CCP) ~200 ml dose, High Titer K3 Kpa Antigen Type 11 Red Blood Cells - Washing Fee FY1 Fya Antigen Type 12 Red Blood Cells - Freezing and Deglycerolization Fee FY2 Fyb Antigen Type 14 CMV Negative Blood Product (Available Inventory) JK1 Jka Antigen Type 34 Platelet Washing Fee (plus plasma) JK2 Jkb Antigen Type LVDS Platelet Large Volume Delayed Sampling Fee Non-refundable on returned units LE1 Lea Antigen Type L16 STAT Component Modification Fee LE2 Leb Antigen Type 98 Irradiation Procedure Fee P1 P1 Antigen Type CPD CPD Manufacturing Fee DI3 Wra Antigen Type 97 Directed Donor Handling Fee AB4 A1 Type - Lectin A1 Type 96 Autologous Donor Handling Fee WDV Partial D Weak D Testing 01A ABO-Rh OTH Rare Antigen Type - Ag types requring rare antisera or genotyping 02A Direct Antiglobulin Test (Coombs Test) - single 12B Compatibility Test (Allogeneic) per Unit - Full Crossmatch (AHG) The contractor shall have the following licenses and or registrations: a The Contractor shall maintain an unrevoked U. S. License which is issued by the Director, Bureau of Biologics, FDA under Section 351 of the Public Health Service Act, as amended, 42 USC Section 262, as a source of supply for whole blood. b. If the Contractor is involved in interstate shipment of blood or blood component is involved, the Contractor must maintain approval authorized under Section 251 of the Public Health Service Act, as amended, 42 USC Section 262. c. The Contractor's blood bank must maintain registration and/or licensing with the Food and Drug Administration (FDA), Department of Health and Human Services pursuant to Section 510 of the Federal Food, Drug and Cosmetic Act, as amended, 21 USC Section 260 at all times during the contract period. e. Certificate of Accreditation under the Clinical Laboratory Improvement Act of 1988 or current certification by the College of American Pathologists. The anticipated Small Business Administration (SBA) size standard for the North American Industry Classification System (NAICS) code _325410__ is __1,250 Employees__. 3. Responses Requested: The following questions must be answered in response to this RFI. Answers that are not provided shall be considered non-responsive to the RFI: a. Where are the requested items/equipment manufactured? Vendor must attach documentation of this information to be viewed by the government to be considered as part of the Market Research and responsiveness to this Sources Sought notice b. Are the requested items/equipment manufactured by a Small or Large business? Is the potential vendor in compliance with the Non-Manufacturer Rule (NMR)? Vendor must attach documentation of this to be viewed by the government to be considered as part of the Market Research and responsiveness to this Sources Sought notice c. Is the Vendor an authorized distributor with access to Original Equipment Manufacturer (OEM) parts which may be required in performance of this requirement? The VA does not accept grey market items and therefore the Vendor must attach evidence of this access (Authorized Distributor letter) to be viewed by the government to be considered as part of the Market Research and responsiveness to this Sources Sought notice. d. Name of potential Contractor that possess the capability to fulfill this requirement. Contractors shall also provide the following: Point(s) of contact name: _______________________________________________ Address: ___________________________________________________ Telephone number: ___________________________________________ Email address: _______________________________________________ Company's business size: ________________________________________________ Data Universal Numbering System (DUNS) #: _______________________________ e. Is your company considered a small business concern, SB, SDVOSB, VOSB, HUBZone, or 8A concern, with the requisite __________________ NAICS code? Please provide proof of qualifications. f. Is your company available under any Government Wide Agency Contract (GWAC), General Services Administration (GSA) Schedule, Indefinite Delivery Indefinite Quantity (IDIQ), and/or Blanket Purchase Agreement (BPA)? If so, please identify the contract number for the Government to review as part of this Market Research. 4. Opportunity/Market Pricing: The MEDVAMC is seeking information from potential vendors on their ability to provide the required items/equipment. THIS IS A SOURCES SOUGHT REQUEST FOR INFORMATION (RFI) ONLY. Small Business Concerns are encouraged to provide responses to this RFI in order to assist the MEDVAMC in determining potential levels of competition and general market pricing available in the industry. Therefore, vendors are requested to submit estimated market research pricing along with their responses to the above. The estimated pricing will be considered when determining the procurement strategy for the forthcoming solicitation. 5. Instructions and Response Guidelines: Questions regarding this RFI shall be submitted no later than 3:00pm (CST), October 13, 2022, via email to lakeisha.white@va.gov. RFI responses are due by 3:00pm (CST), Thursday, October 13, 2022; size is limited to 8.5 x 11 inches, 12-point font, with 1-inch margins in Microsoft Word format via email to lakeisha.white@va.gov The subject line shall read: MEDVAMC Blood and Blood Products Sources Sought. NO SOLICITATION EXISTS AT THIS TIME. There is no page limitation on subparagraphs 3(a) - 3(f). Please provide the information you deem relevant in order to respond to the specific inquiries of the RFI. Information provided will be used solely by MEDVAMC as Market Research and will not be released outside of the MEDVAMC Purchasing and Contract Team. 7. Contact Information: Lakeisha White Lakeisha.white@va.gov Your response to this notice is greatly appreciated!
- Web Link
-
SAM.gov Permalink
(https://sam.gov/opp/072ffd378ec445ca82eb08f26edb626a/view)
- Record
- SN06489959-F 20221009/221007230117 (samdaily.us)
- Source
-
SAM.gov Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's SAM Daily Index Page |